BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3037 related articles for article (PubMed ID: 22982650)

  • 1. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
    Krawczyk P; Kowalski DM; Krawczyk KW; Szczyrek M; Mlak R; Rolski A; Szudy A; Kieszko R; Winiarczyk K; Milanowski J; Krzakowski M
    Oncol Rep; 2013 Sep; 30(3):1463-72. PubMed ID: 23783797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
    Fiala O; Pesek M; Finek J; Krejci J; Ricar J; Bortlicek Z; Benesova L; Minarik M
    Neoplasma; 2013; 60(1):26-32. PubMed ID: 23067213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
    Metro G; Chiari R; Duranti S; Siggillino A; Fischer MJ; Giannarelli D; Ludovini V; Bennati C; Marcomigni L; Baldi A; Giansanti M; Minotti V; Crinò L
    Lung Cancer; 2012 Oct; 78(1):81-6. PubMed ID: 22770374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.
    Fiala O; Pesek M; Finek J; Minarik M; Benesova L; Bortlicek Z; Topolcan O
    Tumour Biol; 2015 Aug; 36(8):5801-5. PubMed ID: 25702091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
    Beau-Faller M; Texier M; Blons H; Richard N; Escande F; Melaabi S; Lizard S; De Fraipont F; Longchampt E; Morin F; Zalcman G; Pignon JP; Cadranel J
    Clin Lung Cancer; 2019 May; 20(3):222-230. PubMed ID: 30679079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 152.